Dosimetry Recruitment of theranostic prostate trial complete
Filed with ASX · · 3 pages · English
Clarity Pharmaceuticals Ltd. on 6ix
In the deck
Story so far
Earlier from Clarity Pharmaceuticals
- Appendix 4C Cash Flow Report
- Recruitment closed on C-BOBCAT SAR-Bombesin trial
- App 4E Preliminary Final Report 30 June 2021
Later from Clarity Pharmaceuticals
- Quarterly Activity Report
- Managing Directors Presentation to Annual General Meeting
- SARTATE Neuroblastoma trial advances to cohort 2
- Clarity receives $3.26 million R&D tax incentive refund
- US FDA Study May Proceed letter for Cu-64 SAR-bisPSMA
Follow Clarity Pharmaceuticals into a list and get an email when it puts out news.
Follow Clarity Pharmaceuticals